NewswireToday - /newswire/ -
Monrovia, CA, United States, 2012/03/05 - Andrew Merron Ph.D., Biosimilars Advisory Service Product Director at BioTrends (a Decision Resources Company), will be giving a featured presentation at the 2nd Diabetes Summit in Boston, MA - GTCbio.com.
Andrew Merron Ph.D., Biosimilars Advisory Service Product Director at BioTrends, will be giving a featured presentation entitled “Biosimilar Opportunity within the Insulin Market” at the 2nd Diabetes Summit to be held on April 19-20, 2012 in Boston, MA by GTC.
Dr. Merron’s presentation will forecast the commercial future of insulin biosimilars across the seven major pharmaceutical markets based on survey responses of 77 endocrinologists in the United States, France, and Germany as well as the current trends in sales for branded insulins.
Benefits of the presentation:
1. Learn about the current regulatory requirements for approval of biosimilar versions of insulin;
2. Understand current endocrinologist awareness and perceptions of biosimilar versions of insulin;
3. Realize what clinical trial burden endocrinologists expect for biosimilar insulins;
4. See the forecasted market potential for biosimilar insulins.
Prior to managing the Biosimilars Advisory Service, Dr. Merron was a senior analyst in the oncology department at Decision Resources. Dr. Merron has extensive experience in forecasting oncology and hematology-oncology drug markets. Dr. Merron also has considerable experience in conducting primary research with physicians and payers across the major pharmaceutical markets. Through his analyses, Dr. Merron identifies key market findings and highlights their strategic importance. Prior to joining Decision Resources, Dr. Merron received his B.Sc. in biochemistry from the University of Bath and his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses.
With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
Come and join other diabetes experts at GTC’s 2nd Diabetes Summit and hear key thought-leader's opinions to these questions and many more. This important meeting will be held on April 19-20, 2012 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
The 2nd Diabetes Summit will consist of 2 tracks:
5th Diabetes Drug Discovery and Development
2nd Diabetes Partnering & Deal Making.